Home » Stocks » HARP

Harpoon Therapeutics, Inc. (HARP)

Stock Price: $10.67 USD 0.50 (4.92%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
After-hours: $10.10 -0.57 (-5.34%) Jul 28, 4:59 PM
Market Cap 343.78M
Revenue (ttm) 23.15M
Net Income (ttm) -99.08M
Shares Out 31.58M
EPS (ttm) -3.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $10.67
Previous Close $10.17
Change ($) 0.50
Change (%) 4.92%
Day's Open 10.41
Day's Range 10.08 - 10.77
Day's Volume 1,283,384
52-Week Range 9.87 - 25.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Investors need to pay close attention to Harpoon Therapeutics (HARP) stock based on the movements in the options market lately.

4 weeks ago - Zacks Investment Research

Harpoon Therapeutics Inc (NASDAQ: HARP) provides updated interim data from the ongoing dose-escalation portion of the Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostat...

1 month ago - Benzinga

SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provid...

1 month ago - GlobeNewsWire

Harpoon Therapeutics Inc (NASDAQ: HARP) has announced interim data from the ongoing dose-escalation portion of a Phase 1/2a trial evaluating HPN424 in patients with metastatic castration-resistant prost...

1 month ago - Benzinga

Management to host webcast and conference call to provide a pipeline update at 4 p.m. ET / 1 p.m. PT on June 4, 2021 Management to host webcast and conference call to provide a pipeline update at 4 p.m....

2 months ago - GlobeNewsWire

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 13.95% and 32.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs

2 months ago - GlobeNewsWire

Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today annou...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today annou...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today annou...

4 months ago - GlobeNewsWire

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 22.41% and 52.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the s...

4 months ago - Zacks Investment Research

Provided positive update on its four TriTAC ® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today annou...

4 months ago - GlobeNewsWire

Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...

5 months ago - GlobeNewsWire

Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.

6 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...

6 months ago - GlobeNewsWire

Underwriters Fully Exercise Option to Purchase Additional Shares Underwriters Fully Exercise Option to Purchase Additional Shares

6 months ago - GlobeNewsWire

Harpoon (HARP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced to...

6 months ago - GlobeNewsWire

HPN328, Harpoon's fourth TriTAC® T cell engager, enters clinical development HPN328, Harpoon's fourth TriTAC® T cell engager, enters clinical development

6 months ago - GlobeNewsWire

Harpoon Therapeutics presents an opportunity in the cancer treatment space, and at the current levels, the stock is a good buy. HPN424, HARP's most advanced product, targets prostate cancer, which alone...

6 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclin...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, announced today that th...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today report...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announ...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today ann...

10 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today anno...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today repo...

11 months ago - GlobeNewsWire

Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today anno...

1 year ago - GlobeNewsWire

Initiation of the clinical trial triggers $50 million milestone payment from AbbVie Initiation of the clinical trial triggers $50 million milestone payment from AbbVie

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today ann...

1 year ago - GlobeNewsWire

The American Society of Clinical Oncology's annual meeting -- one of the most important healthcare industry gatherings of the year -- will happen without face-to-face contact.

Other stocks mentioned: TRIL
1 year ago - The Motley Fool

Harpoon Therapeutics, Inc. (HARP) CEO Gerald McMahon on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor in Harpoon Therapeutics, Inc. (HARP).

1 year ago - Zacks Investment Research

Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year

Other stocks mentioned: ABBV
1 year ago - GlobeNewsWire

HPN328, a TriTAC®, Exhibits the Potency, Tolerability, and Pharmacokinetics to Support Initiation of Clinical Development in 2020

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today anno...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today anno...

1 year ago - GlobeNewsWire

Tag along on two of them -- but watch out for this biotech upstart, on which Wall Street might be a little early.

Other stocks mentioned: CRM, RGLD
2 years ago - The Motley Fool

About HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the t... [Read more...]

Industry
Biotechnology
IPO Date
Feb 8, 2019
CEO
Gerald McMahon
Employees
84
Stock Exchange
NASDAQ
Ticker Symbol
HARP
Full Company Profile

Financial Performance

In 2020, HARP's revenue was $17.44 million, an increase of 201.96% compared to the previous year's $5.78 million. Losses were -$49.91 million, -10.19% less than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for HARP stock is "Strong Buy." The 12-month stock price forecast is 29.30, which is an increase of 174.60% from the latest price.

Price Target
$29.30
(174.60% upside)
Analyst Consensus: Strong Buy